Dr. Elizabeth J. Davis
Claim this profileVanderbilt University/Ingram Cancer Center
About Elizabeth J. Davis
Education:
- Obtained MD from Vanderbilt University School of Medicine in 2009.
- Completed Residency in Internal Medicine at Vanderbilt University Medical Center in 2012.
- Finished Fellowship in Hematology/Oncology at Vanderbilt University Medical Center in 2015.
Experience:
- Specializes in hematology and oncology at Ingram Cancer Center, Vanderbilt University Medical Center.
- Serves as Assistant Professor of Medicine at Vanderbilt University Medical Center.
Area of expertise
Cancer
Elizabeth J. Davis has run 10 trials for Cancer. Some of their research focus areas include:
Soft Tissue Sarcoma
Elizabeth J. Davis has run 9 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Affiliated Hospitals
Vanderbilt University/Ingram Cancer Center
Vanderbilt Breast Center At One Hundred Oaks
Clinical Trials Elizabeth J. Davis is currently running
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
INBRX-109
for Solid Tumors
This trial tests INBRX-109, a protein that attaches to harmful cells and signals the body to destroy them. It targets patients with conditions involving DR5, like certain cancers.
Recruiting
1 award
Phase 1
2 criteria
More about Elizabeth J. Davis
Clinical Trial Related
6 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Elizabeth J. Davis has experience with
- Pembrolizumab
- INBRX-109
- Atezolizumab
- Olaparib
- 9-ING-41
- Toripalimab
Breakdown of trials Elizabeth J. Davis has run
Cancer
Soft Tissue Sarcoma
Malignant Fibrous Histiocytoma
Soft tissue sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elizabeth J. Davis specialize in?
Elizabeth J. Davis focuses on Cancer and Soft Tissue Sarcoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Elizabeth J. Davis currently recruiting for clinical trials?
Yes, Elizabeth J. Davis is currently recruiting for 2 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Elizabeth J. Davis has studied deeply?
Yes, Elizabeth J. Davis has studied treatments such as Pembrolizumab, INBRX-109, Atezolizumab.
What is the best way to schedule an appointment with Elizabeth J. Davis?
Apply for one of the trials that Elizabeth J. Davis is conducting.
What is the office address of Elizabeth J. Davis?
The office of Elizabeth J. Davis is located at: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University/Ingram Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.